Massimo Moltrasio

Massimo Moltrasio

Auto-generated profile, based on publicly available information

Massimo Moltrasio

Department of Clinical Electrophysiology and Cardiac Pacing, Centro Cardiologico Monzino IRCCS , Via Carlo Parea 4, Milan 20138

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 March 2024 in Journal of Cardiovascular Electrophysiology
Verified
Journal Article
Open access
SMSchiavone Marco
Schiavone Marco
FSFrancesco Solimene
Francesco Solimene
MMMassimo Moltrasio
Massimo Moltrasio
Michela CasellaMichela Casella
Michela Casella
SBStefano Bianchi
Stefano Bianchi
CTClaudio Tondo
Claudio Tondo
Introduction: Limited data exist on pulsed‐field ablation (PFA) in patients with persistent atrial fibrillation (PeAF) undergoing left atrial posterior wall isolation (LAPWI).Methods: The Advanced TecHnologies For SuccEssful AblatioN of AF in Clinical Practice (ATHENA) prospective registry included consecutive patients referred for PeAF catheter ablation at 9 Italian centers, treated with the FARAPULSETM‐PFA system. The primary efficacy and safety study endpoints were the acute LAPWI rate, freedom from arrhythmic recurrences and the incidence of major periprocedural complications. Patients undergoing pulmonary vein isolation (PVI) alone, PWI + LAPWI and redo procedures were compared.Results: Among 249 patients, 21.7% had long‐standing PeAF, 79.5% were male; mean age was 63 ± 9 years. LAPWI was performed in 57.6% of cases, with 15.3% being redo procedures. Median skin‐to‐skin times (PVI‐only 68 [60−90] vs. PVI + LAPWI 70 [59−88] mins) did not differ between groups. 45.8% LAPWI cases were approached with a 3D‐mapping system, and 37.3% with intracardiac echocardiography. LAPWI was achieved in all patients by means of PFA alone, in 88.8% cases at first pass. LAPWI was validated either by an Ultrahigh‐density mapping system or by recording electrical activity + pacing maneuvers. No major complications occurred, while 2.4% minor complications were detected. During a median follow‐up of 273 [191–379] days, 41 patients (16.5%) experienced an arrhythmic recurrence after the 90‐day blanking period, with a mean time to recurrence of 223 ± 100 days and no differences among ablation strategies.Conclusion: LAPWI with PFA demonstrates feasibility, rapidity, and safety in real‐world practice, offering a viable alternative for PeAF patients. LAPWI is achievable even with a fluoroscopy‐only method and does not significantly extend overall procedural times.

17 March 2026 in EP Europace
Verified
Journal Article
Open access
SMSchiavone Marco
Schiavone Marco
FSFrancesco Solimene
Francesco Solimene
ARAntonio Dello Russo
Antonio Dello Russo
SBStefano Bianchi
Stefano Bianchi
Saverio IacopinoSaverio Iacopino
Saverio Iacopino
CTClaudio Tondo
Claudio Tondo
Aims: Data on pulsed-field ablation (PFA) for atrial fibrillation (AF) in patients with heart failure (HF) are limited. To evaluate clinical outcomes of PFA in patients with AF and HF, stratified by HF subtype. Methods and Results: Consecutive patients undergoing first-time pentaspline PFA within the ATHENA registry were analyzed. Patients were stratified into three groups: no HF, HF with preserved ejection fraction (HFpEF, LVEF ≥50%), and HF with mildly reduced or reduced EF (HFmrEF/rEF, LVEF 30 s after a 2-month blanking period. AAD use was left to physician discretion. Among 1,224 patients included (68.5% with paroxysmal AF and 31.5% with persistent AF), 176 (14.4%) had HF: 40 (3.3%) with HFpEF and 136 (11.1%) with HFmrEF/rEF. The Kaplan-Meier estimated freedom from any atrial arrhythmias at 1-year follow-up was 79.9%, with higher rate in the no-HF group (81.0%) vs the HF group (73.3%, HR = 1.5, 95% CI: 1.1–2.1, P = 0.0133). Considering separately paroxysmal and persistent AF form, paroxysmal AF patients with no sign of HF showed significantly higher freedom from atrial arrhythmias (82.2%) than patients with HF (68.6%, 2.0, 1.3–3.1, P = 0.0028), while no differences were found in patients with persistent AF (77.9% vs 76.4%, 1.1, 0.7–1.7, P = 0.7065). Conclusion: PFA with the pentaspline catheter appears to be an effective treatment for AF in patients with HF. Freedom from AF and atrial arrhythmias post-PFA was highest in patients with paroxysmal AF and no history of HF, with no significant differences observed in persistent AF patients. Clinical Trial Registration: Advanced TecHnologies For SuccEssful AblatioN of AF in Clinical Practice (ATHENA). URL: http://clinicaltrials.gov/Identifier: NCT05617456.

9 September 2020 in Journal of Cardiovascular Electrophysiology
Verified
Journal Article
Closed access
PDF file
MMMassimo Moltrasio
Massimo Moltrasio
AKAdriano Nunes Kochi
Adriano Nunes Kochi
GFGaetano Fassini
Gaetano Fassini
SRStefania Riva
Stefania Riva
FTFabrizio Tundo
Fabrizio Tundo
CTClaudio Tondo
Claudio Tondo

8 July 2025 in EP Europace
Verified
Journal Article
Open access
MMMassimo Moltrasio
Massimo Moltrasio
Saverio IacopinoSaverio Iacopino
Saverio Iacopino
FSFrancesco Solimene
Francesco Solimene
SBStefano Bianchi
Stefano Bianchi
SMSchiavone Marco
Schiavone Marco
CTClaudio Tondo
Claudio Tondo
Clinical trial registration: Advanced TecHnologies For SuccEssful AblatioN of AF in Clinical Practice (ATHENA). URL: http://clinicaltrials.gov/Identifier: NCT05617456.